10x Genomics (TXG) | Financial Analysis & Statements
Financial Overview
Latest Annual: 2024Income Metrics
Revenue
610.8M
Gross Profit
414.5M
67.86%
Operating Income
-194.6M
-31.85%
Net Income
-182.6M
-29.90%
EPS (Diluted)
-$1.52
Balance Sheet Metrics
Total Assets
918.6M
Total Liabilities
208.5M
Shareholders Equity
710.1M
Debt to Equity
0.29
Cash Flow Metrics
Operating Cash Flow
18.2M
Free Cash Flow
-6.7M
Revenue & Profitability Trend
10x Genomics Income Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 610.8M | 618.7M | 516.4M | 490.5M | 298.8M |
| Cost of Goods Sold | 196.3M | 209.4M | 120.4M | 74.1M | 58.5M |
| Gross Profit | 414.5M | 409.3M | 396.0M | 416.4M | 240.4M |
| Operating Expenses | 609.0M | 613.7M | 564.0M | 469.3M | 327.0M |
| Operating Income | -194.6M | -204.3M | -167.9M | -52.9M | -85.3M |
| Pre-tax Income | -177.7M | -248.8M | -162.0M | -53.7M | -534.5M |
| Income Tax | 4.9M | 6.3M | 4.0M | 4.5M | 8.3M |
| Net Income | -182.6M | -255.1M | -166.0M | -58.2M | -542.7M |
| EPS (Diluted) | -$1.52 | -$2.18 | -$1.46 | -$0.53 | -$5.37 |
Income Statement Trend
10x Genomics Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | 584.4M | 596.0M | 635.0M | 747.6M | 774.4M |
| Non-Current Assets | 334.2M | 369.1M | 393.9M | 271.2M | 155.0M |
| Total Assets | 918.6M | 965.1M | 1.0B | 1.0B | 929.3M |
| Liabilities | |||||
| Current Liabilities | 117.6M | 127.2M | 131.0M | 110.4M | 118.1M |
| Non-Current Liabilities | 90.9M | 96.9M | 92.3M | 90.9M | 72.1M |
| Total Liabilities | 208.5M | 224.1M | 223.2M | 201.3M | 190.3M |
| Equity | |||||
| Total Shareholders Equity | 710.1M | 741.0M | 805.7M | 817.6M | 739.1M |
Balance Sheet Composition
10x Genomics Cash Flow Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -182.6M | -255.1M | -166.0M | -58.2M | -542.7M |
| Operating Cash Flow | 18.2M | -53.1M | -34.4M | 24.6M | -215.6M |
| Investing Activities | |||||
| Capital Expenditures | -12.4M | -48.6M | -131.7M | -101.3M | -36.7M |
| Investing Cash Flow | -31.6M | 134.4M | -350.9M | -106.7M | -36.7M |
| Financing Activities | |||||
| Dividends Paid | - | - | - | - | - |
| Financing Cash Flow | - | -5.8M | -5.4M | -5.0M | 445.2M |
| Free Cash Flow | -6.7M | -64.7M | -165.3M | -122.7M | -256.3M |
Cash Flow Trend
10x Genomics Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-7.23
Forward P/E
-8.93
Price to Book
1.90
Price to Sales
2.15
PEG Ratio
-8.93
Profitability Ratios
Profit Margin
-25.14%
Operating Margin
-31.33%
Return on Equity
-22.03%
Return on Assets
-12.43%
Financial Health
Current Ratio
5.37
Debt to Equity
11.33
Beta
1.98
Per Share Data
EPS (TTM)
-$1.30
Book Value per Share
$5.74
Revenue per Share
$5.15
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| txg | 1.3B | -7.23 | 1.90 | -22.03% | -25.14% | 11.33 |
| Veeva Systems | 46.0B | 59.92 | 7.39 | 14.06% | 27.34% | 1.24 |
| Ge Healthcare | 32.6B | 14.95 | 3.55 | 26.44% | 11.03% | 97.52 |
| Premier | 1.9B | 21.46 | 1.18 | 6.85% | 4.96% | 19.35 |
| Certara | 1.7B | 104.00 | 1.56 | -0.25% | -0.67% | 28.51 |
| Schrodinger | 1.5B | 44.39 | 4.05 | -43.33% | -83.39% | 31.15 |
Financial data is updated regularly. All figures are in the company's reporting currency.